The approval was based on the results of a clinical trial that demonstrated improved PFS in patients on lanreotide. While the median PFS in the placebo arm was 16 months, patients in the lanreotide ...

An interim analysis of somatostatin analog lanreotide depot presented at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, found that the ...

Review the side-effects of Lanreotide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

SAN DIEGO — Lanreotide treatment for patients with later-stage autosomal dominant polycystic kidney disease (ADPKD) did not appear to slow patients’ decline in kidney function compared with standard ...

Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus ...

The somatostatin analogue lanreotide (Somatuline, Ipsen) is significantly better than placebo for controlling progression of many types of metastatic neuroendocrine tumors (NETs), according to the ...

Insulin-like growth factor I and growth hormone levels were adequately controlled on 4-weekly injections in nine patients. In these patients the effect of increasing the time interval between ...

The reality of pancreas cancer care from access to delivery. Background: Somatostatin analogues in previous open label studies improved symptoms due to bowel obstruction in patients with peritoneal ...

Lanreotide autogel did not increase lipid or glucose levels in patients with acromegaly, researchers conducting an open-label phase 3b study found. The researchers reported that only a small minority ...

A 35-year-old man had a clinical picture suggestive of the ectopic corticotropin syndrome related to a carcinoid tumor; biochemical and hormonal tests confirmed the diagnosis. Somatostatin-receptor ...